Browse the latest research summaries in the field of oncology for spinal cord injury patients and caregivers.
Showing 161-170 of 200 results
Cells, 2023 • June 21, 2023
This study provides a detailed characterization of the galanin (GAL) system in the human bile duct and perihilar cholangiocarcinoma (pCCA), examining the expression of GAL and its receptors (GAL1–3-R)...
KEY FINDING: GAL and GAL1-R were expressed in various bile duct cell types, GAL2-R was slightly expressed, and GAL3-R specifically in cholangiocytes and capillaries.
Metabolites, 2023 • August 3, 2023
The study investigates the efficacy of combining a ketogenic diet (KD), metformin (MET), and metronomic cyclophosphamide (CP) as a triple therapy for MYCN-amplified neuroblastoma (NB). Results showed ...
KEY FINDING: MET reduces cell proliferation and mitochondrial respiration in MYCN-amplified NB cell lines.
Discover Oncology, 2023 • August 7, 2023
This study identifies Caveolin-1 (CAV1) as a key gene involved in glioma progression and resistance to oxidative phosphorylation (OXPHOS) inhibitors. The researchers found that CAV1 is highly expresse...
KEY FINDING: CAV1 is highly expressed in gliomas and its expression is positively related with pathological processes, higher CAV1 predicts shorter overall survival.
CNS Neuroscience & Therapeutics, 2024 • January 1, 2024
CNS tumors are complex diseases with specific pathogeneses not fully understood and poor prognosis, often resistant to therapies. ncRNAs, including circRNAs, significantly contribute to tumor initiati...
KEY FINDING: CircRNAs participate in multiple molecular mechanisms of cellular normal or pathophysiology processes, especially as miRNA sponges in the cytoplasm, activating the modulation of target genes via miRNA response elements.
Genome Medicine, 2023 • December 2, 2023
The study introduces comboSC, a computational prototype for personalized cancer combination therapy optimization using single-cell transcriptomes. ComboSC stratifies individual patient samples based o...
KEY FINDING: ComboSC can predict potential drug combinations for experimental validation and clinical usage using the single-cell transcriptome.
Journal of Hematology & Oncology, 2024 • March 11, 2024
This study investigates the proteomic landscape of esophageal squamous cell carcinoma (ESCC) in response to anti-PD1 immunotherapy to identify resistance mechanisms and predictive markers. The researc...
KEY FINDING: Immune and mitochondrial functions are associated with ESCC immunotherapy sensitivity.
Advanced Science, 2024 • June 19, 2024
This study reveals that CKB promotes mitochondrial ATP production by inhibiting AKT activation, which in turn reduces mitochondrial calcium levels and mPTP activity. The CKB-AKT signaling axis plays a...
KEY FINDING: CKB is essential for maintaining cellular sensitivity to F1F0 ATP synthase inhibition, a key enzyme in mitochondrial ATP production.
Frontiers in Immunology, 2024 • July 4, 2024
This study demonstrates that MVP is markedly increased in PAAD tissues and correlated with an adverse prognosis. Related analyses confirmed its potential as a novel diagnostic and prognostic indicator...
KEY FINDING: MVP is abnormally upregulated in PAAD tissues and correlates with adverse prognosis.
Communications Biology, 2024 • December 2, 2024
The study provides a single-cell level atlas characterizing the tumor microenvironment (TME) in primary and recurrent multifocal bladder cancer (BLCA). Analyses reveal significant differences in malig...
KEY FINDING: Malignant cells from recurrent multifocal bladder cancer exhibited higher interregional transcriptional similarity and consistent cellular communication.
Frontiers in Pharmacology, 2024 • August 13, 2024
The study introduces Mn-doped ZIF nanozymes as a novel approach to tumor therapy. These nanozymes leverage the high H2O2 concentration in tumor microenvironments to generate hydroxyl radicals, directl...
KEY FINDING: Mn-ZIF nanozymes possess peroxidase (POD) activity, enabling them to oxidize tumor-localized H2O2 into hydroxyl radicals (·OH), effectively killing tumor cells.